Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia.

RATIONALE Pseudomonas aeruginosa is one of the leading causes of gram-negative ventilator-associated pneumonia (VAP) associated with a mortality rate of 34 to 68%. Recent evidence suggests that P. aeruginosa in patients with VAP may persist in the alveolar space despite adequate antimicrobial therapy. We hypothesized that failure to eradicate P. aeruginosa from the lung is linked to type III secretory system (TTSS) isolates. OBJECTIVES To determine the mechanism by which infection with P. aeruginosa in patients with VAP may evade the host immune response. METHODS Thirty-four patients with P. aeruginosa VAP underwent noninvasive bronchoalveolar lavage (BAL) at the onset of VAP and on Day 8 after initiation of antibiotic therapy. Isolated pathogens were analyzed for secretion of type III cytotoxins. Neutrophil apoptosis in BAL fluid was quantified by assessment of nuclear morphology on Giemsa-stained cytocentrifuge preparations. Neutrophil elastase was assessed by immunoenzymatic assay. MEASUREMENTS AND MAIN RESULTS Twenty-five out of the 34 patients with VAP secreted at least one of type III proteins. There was a significant difference in apoptotic rate of neutrophils at VAP onset between those strains that secreted cytotoxins and those that did not. Neutrophil elastase levels were positively correlated with the rate of apoptosis (r = 0.43, P < 0.01). Despite adequate antimicrobial therapy, 13 out of 25 TTSS(+) isolates were recovered at Day 8 post-VAP, whereas eradication was achieved in all patients who had undetectable levels of type III secretion proteins. CONCLUSIONS The increased apoptosis in neutrophils by the TTSS(+) isolates may explain the delay in eradication of Pseudomonas strains in patients with VAP. Short-course antimicrobial therapy may not be adequate in clearing the infection with a TTSS secretory phenotype.

[1]  Mauricio Valencia,et al.  Ventilator-associated pneumonia , 2009, Current opinion in critical care.

[2]  F. Sutterwala,et al.  Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome , 2007, The Journal of experimental medicine.

[3]  D. Glidden,et al.  Increased Plasminogen Activator Inhibitor-1 Concentrations in Bronchoalveolar Lavage Fluids Are Associated with Increased Mortality in a Cohort of Patients with Pseudomonas aeruginosa , 2007, Anesthesiology.

[4]  M. Schultz,et al.  Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: Role of bacterial pathogens* , 2007, Critical care medicine.

[5]  R. Ramphal,et al.  Neutrophil Elastase, an Innate Immunity Effector Molecule, Represses Flagellin Transcription in Pseudomonas aeruginosa , 2006, Infection and Immunity.

[6]  S. McColley,et al.  Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.

[7]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[8]  J. Coburn,et al.  Characterization of Pseudomonas aeruginosa Exoenzyme S as a Bifunctional Enzyme in J774A.1 Macrophages , 2003, Infection and Immunity.

[9]  M. Riese,et al.  Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins , 2002, Molecular microbiology.

[10]  Anna L Jansson,et al.  Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) activities towards small GTPases in vivo. , 2002, The Biochemical journal.

[11]  J. Rello,et al.  Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2002, Critical Care Medicine.

[12]  G. Taylor,et al.  Induction of Neutrophil Apoptosis by the Pseudomonas aeruginosa Exotoxin Pyocyanin: A Potential Mechanism of Persistent Infection1 , 2002, The Journal of Immunology.

[13]  J. Barbieri,et al.  In Vivo Rho GTPase-Activating Protein Activity of Pseudomonas aeruginosa Cytotoxin ExoS , 2002, Infection and Immunity.

[14]  N. Shime,et al.  Therapeutic Administration of Anti-PcrV F(ab′)2 in Sepsis Associated with Pseudomonas aeruginosa1 , 2001, The Journal of Immunology.

[15]  D. Frank,et al.  Multiple Domains Are Required for the Toxic Activity of Pseudomonas aeruginosa ExoU , 2001, Journal of bacteriology.

[16]  R. Savel,et al.  Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. , 2001, The Journal of infectious diseases.

[17]  K. Aktories,et al.  Pseudomonas aeruginosa ExoT Is a Rho GTPase-Activating Protein , 2000, Infection and Immunity.

[18]  U. Ha,et al.  Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of exoS. , 2000, Microbiology.

[19]  G. Pier,et al.  Acquisition of Expression of the Pseudomonas aeruginosa ExoU Cytotoxin Leads to Increased Bacterial Virulence in a Murine Model of Acute Pneumonia and Systemic Spread , 2000, Infection and Immunity.

[20]  H. Katus,et al.  Decreased apoptosis and increased activation of alveolar neutrophils in bacterial pneumonia. , 2000, Chest.

[21]  J. Croizé,et al.  Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils , 2000, Infection and Immunity.

[22]  K. Aktories,et al.  The N-terminal Domain of Pseudomonas aeruginosaExoenzyme S Is a GTPase-activating Protein for Rho GTPases* , 1999, The Journal of Biological Chemistry.

[23]  B. Toussaint,et al.  Cell Death of Human Polymorphonuclear Neutrophils Induced by a Pseudomonas aeruginosa Cystic Fibrosis Isolate Requires a Functional Type III Secretion System , 1999, Infection and Immunity.

[24]  Y. Carmeli,et al.  Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents , 1999, Antimicrobial Agents and Chemotherapy.

[25]  J. Wiener-Kronish,et al.  Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury , 1999, Nature Medicine.

[26]  T. Yahr,et al.  Biological Effects of Pseudomonas aeruginosa Type III-Secreted Proteins on CHO Cells , 1999, Infection and Immunity.

[27]  J. Barbieri,et al.  ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Barbieri,et al.  Intracellular expression of the ADP‐ribosyltransferase domain of Pseudomonas exoenzyme S is cytotoxic to eukaryotic cells , 1998, Molecular microbiology.

[29]  Michael A. Gropper,et al.  In Vitro Cellular Toxicity PredictsPseudomonas aeruginosa Virulence in Lung Infections , 1998, Infection and Immunity.

[30]  C. Hueck,et al.  Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants , 1998, Microbiology and Molecular Biology Reviews.

[31]  J. Rello,et al.  Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? , 1998, American journal of respiratory and critical care medicine.

[32]  J. Engel,et al.  PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence , 1998, Molecular microbiology.

[33]  Lei Zhu,et al.  ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury , 1997, Molecular microbiology.

[34]  J. Savill,et al.  Actin is cleaved during constitutive apoptosis. , 1997, The Biochemical journal.

[35]  S. Fleiszig,et al.  Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S , 1997, Infection and immunity.

[36]  T. Yahr,et al.  Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway , 1996, Molecular microbiology.

[37]  M. Rué,et al.  Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  R. Wunderink,et al.  Ventilator-associated pneumonia due to Pseudomonas aeruginosa. , 1996, Chest.

[39]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[40]  J. Pittet,et al.  Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury. , 1994, The American journal of physiology.

[41]  J. Rello,et al.  Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. , 1993, Chest.

[42]  P. Montravers,et al.  Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. , 1993, The American journal of medicine.

[43]  J. Lupski,et al.  Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. , 1991, Nucleic acids research.

[44]  M. Walport,et al.  Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. , 1989, The Journal of clinical investigation.

[45]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[46]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[47]  R. Wenzel,et al.  Epidemiology of infections due to Pseudomonas aeruginosa. , 1984, Reviews of infectious diseases.

[48]  B. Iglewski,et al.  Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S , 1984, Infection and immunity.

[49]  P. Henson,et al.  Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages , 1982, The Journal of experimental medicine.

[50]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.